Our Mission: empower the next generation of biotech leaders
For years, early-career scientists have struggled to access the mentorship, networks, and community needed to transform bold ideas into real-world impact.
Nucleate was created to ensure they never have to face that journey alone — and to provide the kind of support so many of us wish we had earlier in our own careers.
Our Challenge: leave the ladder down for the next generation of innovators during these uncertain times
To remain mission-aligned, independent, & accessible for the next 20 years, Nucleate needs a stable philanthropic foundation — built by the people who know us best: our mentors, advisors, and industry supporters.
Introducing Nucleate’s Leadership Council
A Leadership Community Shaping the Future of Nucleate
Members join a curated group of life science leaders and disruptors committed to leaving the ladder down for the next generation.
Membership Includes
Annual virtual “State of Nucleate” council meeting to help shape our organization’s future
Early exposure to standout innovation and talent across our global community
Preferred access to Nucleate events, including complimentary Summit registration
Recognition as a champion of the next generation on our website, impact report, and digital LinkedIn badge
The Leadership Council will play a critical role in sustaining the financial stability of Nucleate. We ask that you support this cause by donating $5,000 each year, or more if you can, to Nucleate as an expectation of being a member of the Leadership Council. Donations can be made anytime during the calendar year. As a 501(c)3 non-profit, your donation to Nucleate is tax deductible.
GREG ERMAN, Chairman NLC President & CEO Luzatu TherapeuticsChris Garabedian CEO XontogenyAdam Jenkins Regional Director BioLabsJohn Cumbers Founder & CEO SynBioBetaChandra Ramanathan Board Chair NucleateTere Williams CEO DUB TherapeuticsSamuel Kessel Senior Associate Locust WalkSheila Gujrathi Managing Director SilverArc capitalFrancesca Devine Co-Founder, Managing Partner Devine Insights GroupWarren Browne Partner Citrin CoopermanJeffrey Koury President ResearchHub FoundationVas Bailey General Partner AnomalyLou Lieto Partner Wilson SonsiniDan Goddard Director CFGOLeonard Smith Tax Partner WithumSarah Cork Managing Partner Cork Maloney LLP Lida Kourita Physician Gladstone InstitutesReginald Swift Founder & CEO Rubix LSMandi Williams Contract Specialist WashU St. LouisJosie Kishi Co-Founder Digital BiologyJulien Pham Founder & Managing Partner Third Culture CapitalMichal Preminger CEO BioMed X Venture LabsPeter Barrett Partner Atlas VentureAnn DeWitt General Partner Engine VenturesBen Kromnick General Manager RhoLara Zibners Co-founder, Chair Calla Lily Clinical CareCheri Ackerman Araromi CEO Concerto BiosciencesBrock Reeve CEO Eos BioInnovationJo Viney Cofounder, President & CEO Seismic Therapeutic
Join the Council
We invite you to become a founding member of the leadership council.
“Participating in Nucleate was critical in helping us prioritize our efforts and forge a path to get the company started. I don’t think we would have been as successful without the resources provided by the accelerator program and the people who helped along the way.”
– IVANA VASIC CEO, VITRA LABS
“Nucleate was so transformational—it changed my life, my career choices, and how I think about problem-solving and scaling organizations. You just don’t get this kind of experience in grad school.”
– MICHAEL RETCHIN FORMER CO-PRESIDENT, NUCLEATE CEO, SCALE MEDICINE
“We can’t lead in biotech if we cut the legs out from under early-stage innovation. Programs like Nucleate are important — they keep the pipeline alive by empowering young scientists to turn bold ideas into real breakthroughs.
That’s the kind of future we should be investing in.”
– CONGRESSMAN JAKE AUCHINCLOSS MASSACHUSETTS, FOURTH DISTRICT
Build the future of biotech with us.
Your Support Matters
Your support is a direct investment in the discoveries, therapies, and companies that will shape humanity’s future.
Nucleate's Activator forms pioneering biotech companies without taking equity. Timeline and FAQ.
Deadline for US chapters is October 21st. Deadline for international chapters will vary. Please contact your local chapter to verify.
REQUIREMENTS
01
Approval from PI
02
Well defined technology / product backed by preliminary scientific research (Therapeutic modalities - Platform technologies - Diagnostics - Medical Devices)
03
Existing IP to protect the technology, or clear path to file IP within the next year
04
Clear potential to apply the technology
05
Team intending and willing to 'spin-out' in the near future
This site uses cookies to ensure that you get the best experience possible.